NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LESCOL XL is an extended-release oral tablet containing fluvastatin sodium, a statin used to reduce cholesterol and triglycerides in patients at risk for cardiovascular disease. It is a small-molecule HMG-CoA reductase inhibitor that lowers LDL cholesterol and reduces cardiovascular events in high-risk populations.
$0.722MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal current spending; commercial teams are managing steady decline rather than growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Started Jan 2012
436 enrolled
Lipid Metabolism Disorders
Career Relevance
Working on LESCOL XL offers limited career growth given its LOE status and minimal Part D spending ($722K in 2023). Career progression would focus on portfolio rationalization, price optimization, and managed care negotiations rather than market expansion or innovation.
Brand Manager
Worked on LESCOL XL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.